P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies | Zendy

GC Wishart | Zendy; JA Plumb | Zendy; James J. Going | Zendy; A. M. McNicol | Zendy; CS McArdle | Zendy; T Tsuruo | Zendy; S.B. Kaye | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies

Author(s) -

GC Wishart,

JA Plumb,

James J. Going,

A. M. McNicol,

CS McArdle,

T Tsuruo,

S.B. Kaye

Publication year - 1990

Publication title -

british journal of cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.833

H-Index - 236

eISSN - 1532-1827

pISSN - 0007-0920

DOI - 10.1038/bjc.1990.373

Subject(s) - immunocytochemistry , monoclonal antibody , immunohistochemistry , p glycoprotein , breast cancer , mammary gland , stromal cell , pathology , placental alkaline phosphatase , monoclonal , cancer , medicine , antibody , alkaline phosphatase , biology , cancer research , multiple drug resistance , immunology , drug resistance , enzyme , biochemistry , microbiology and biotechnology

We have investigated P-glycoprotein (P-gp) expression in samples of primary breast cancer from 29 patients before therapy. We employed immunohistochemical techniques using two monoclonal antibodies (C219 and MRK16) and an indirect alkaline phosphatase method. Heterogeneous expression in epithelial cells was detected with both C219 (21 of 29) and MRK16 (16 of 29). A surprising finding was P-glycoprotein expression in stromal cells with both C219 (26 of 29) and MRK16 (12 of 29). Our results suggest that significant levels of P-glycoprotein expression may be present in breast cancer before exposure to drugs associated with multidrug resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research